FIELD: medicine.
SUBSTANCE: invention relates to medicine and to a method for purifying a mixture of cysteine-linked antibody-drug conjugates, wherein the amount of non-conjugated antibody is in the range of 10–40 % by weight. Wherein the method comprises providing the mixture in an aqueous salt solution, loading said solution onto a preparative hydrophobic interaction chromatography column, collecting a flow-through fraction that contains non-conjugated antibody, washing said column with an aqueous salt solution while collecting the flow-through fraction, eluting said column with an aqueous salt solution to obtain a purified mixture of cysteine-linked antibody-drug conjugates. Wherein no added organic solvent is used in either step.
EFFECT: invention provides the increased capacity of the column in binding of antibody-drug conjugates to be purified.
18 cl, 3 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| PROCESS OF LARGE-SCALE PRODUCTION OF CAPPED AND UNCAPPED ANTIBODY CYSTEINES AND THEIR APPLICATION FOR THERAPEUTIC PROTEIN CONJUGATION | 2018 |
|
RU2759602C2 |
| METHOD FOR DOUBLE CONJUGATION FOR OBTAINING ANTIBODY-DRUG CONJUGATES | 2018 |
|
RU2771310C2 |
| MATERIALS AND METHODS ASSOCIATED WITH LINKERS FOR USE IN DRUG AND PROTEIN CONJUGATES | 2015 |
|
RU2737553C2 |
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS | 2015 |
|
RU2670157C2 |
| SITE-SPECIFIC CONJUGATION OF LINKER DRUGS WITH ANTIBODIES AND RESULTING ADC | 2015 |
|
RU2773536C2 |
| ANTIBODY-DRUG CONJUGATES WITH HIGH DRUG LOADING | 2015 |
|
RU2674979C2 |
| ANTIBODY-DRUG CONJUGATES (ADC) WITH DUOCARMICIN USED FOR TREATING ENDOMETRIAL CANCER | 2015 |
|
RU2686085C2 |
| ANTIBODY-DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2787617C2 |
